2026-04-14T15:37:58Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/653442025-03-26T19:10:17Zcom_10324_1138com_10324_931com_10324_894col_10324_1922

Diebold Luque, María Yolanda García Posadas, Laura López Paniagua, Marina De La Mata Sampedro, Ana Galindo de la Rosa, Sara Blázquez, Francisco Calonge, Margarita Nieto Miguel, Teresa Herreras Cantalapiedra, José María Coco Martín, Rosa María Pastor Idoate, Salvador Pastor Jimeno, José Carlos Bhattarchajee, Promita Ahearne, Mark Nagai, Noriaki Sakurai, Shunsuke Seiriki, Ryotaro Minami, Misa Yamaguchi, Mizuki Deguchi, Saori Harata, Eiji Ruíz Alonso, Sandra Villate Beitia, Ilia Lafuente Merchan, Markel Puras, Gustavo Saenz del Burgo, Laura Pedraz, Jose Luis Bosworth, Lucy A Doherty, Kyle G Hsuan, James D Cray, Samuel P D'Sa, Raechelle A Pineda Molina, Catalina Badylak, Stephen F Williams, Rachel L Mirazul Islam, Mohamed AbuSamra, Dina B Chivu, Alexandru Argüeso, Pablo Dohlman, Claes H Patra, Hirak K Chodosh, James González Andrades, Miguel Sánchez Porras, David Caro Magdaleno, Manuel González Gallardo, Carmen García García, Oscar Darío Garzón, Ingrid Carriel, Victor Campos, Fernando Alaminos, Miguel 2024-01-30T13:24:25Z 2024-01-30T13:24:25Z 2021 Diebold, Yolanda; García Posadas, Laura (eds.). Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges. Colección: Pharmaceutics, vol. 13. MDPI, 2021, 224 p. 978-3-0365-2610-2 https://uvadoc.uva.es/handle/10324/65344 10.3390/books978-3-0365-2610-2 Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges The concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. These intend to offer not only regeneration, but complete functional recovery of diseased tissues and organs using different strategies. Gene therapy, cell therapy and tissue engineering are the main areas in which promising advanced therapies are emerging. The eye is a very complex organ whose main structures, the cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs by fighting against the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds and cell stemness, among others—not to mention the complicated legislation around ATMPs, the complexity in production and quality control and the absence of standardized protocols. The purpose of this Special Issue is to serve as an overview of the current progress in the application of cell and gene therapies, as well as tissue engineering to restore functionality in diseased ocular structures, and the challenges they deal with in order to get to patients. eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ © 2021 The Authors Attribution-NonCommercial-NoDerivatives 4.0 Internacional Oftalmología Advanced therapy medicinal products for eye diseases: Goals and challenges info:eu-repo/semantics/book